About: Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $22.92 (-0.97%)
NGNE NASDAQ Neurogene Inc
Neurogene Inc share price
Atividade de preço de NGNE
Último preço
$ 22,920
Variação (24h)
-0,23 USD (0,97%)
Volume
119.16K
Volume (média 4 sem.)
-
Abertura
$ 23,22
Variação do dia
$ 22,52 - $ 23,36
Fechamento anterior
$ 23,14
Último negócio
19 Nov, 9:00 pm GMT+0
Atrasado
19 Nov, 9:00 pm GMT+0
NGNE price performance
Atrasado
19 Nov, 9:00 pm GMT+0
NGNE details
quote.marketSignals